Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Dec 17;13(1):109.
doi: 10.1186/s40200-014-0109-y. eCollection 2014.

Bisphosphonate therapy in pediatric patients

Guiti Eghbali-Fatourechi  1
Affiliations
Review

Bisphosphonate therapy in pediatric patients

Guiti Eghbali-Fatourechi. J Diabetes Metab Disord. .

Abstract

Although for many decades bisphosphonates were used for adult bone loss, bisphosphonate administration in pediatric patients is new and was initiated in the past 15-year. The indications for pediatric bisphosphonates was extended to childhood malignancies with bone involvement, after additional effects were unveiled for bisphosphonates with recent research. In this article we review childhood bone loss and conditions with bone involvement in which bisphosphonate therapy have been used. We also review mechanisms of action of bisphosphonates, and present indications of bisphosphonate therapy in pediatric patients based on results of clinical trials.

Keywords: Bisphosphonate; Corticoid-induced osteoporosis; Nitrogen-containing bisphosphonate; Osteogenesis imperfecta; Pediatric bone loss; Pediatric bone malignancy; Pediatric osteoporosis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Glorieux FH, Bishop N, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947–952. doi: 10.1056/NEJM199810013391402. - DOI - PubMed
    1. Rauch F, Cornibert S, Cheung M, Glorieux FH. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone. 2007;40:821–827. doi: 10.1016/j.bone.2006.11.020. - DOI - PubMed
    1. Ward L, Tricco AC, Phuong P, Cranney A, Barrowman N, Gaboury I, Rauch F, Tugwell P, Moher D. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev. 2007;17(4):CD005324. - PMC - PubMed
    1. Bachrach LK, Ward LM. Clinical review: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab. 2009;94:400–409. doi: 10.1210/jc.2008-1531. - DOI - PubMed
    1. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonates therapy for osyeogenesis imperfecta. Cochrane Database Syst Rev. 2014;7:CD005088. - PubMed

LinkOut - more resources